Company Overview and News

 
Sunrise Asian receives resignation of director

2016-08-11 indiainfoline
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

 
Midcaps continue to outperform in 2016; YES Bank, Biocon, JSW Steel among top gainers

2016-07-04 financialexpress
Midcap stocks continued to show stellar performance on Dalal Street as the BSE Midcap index surged 4.20 per cent in the first half of the ongoing calendar year, whereas benchmark index BSE Sensex advanced 3.21 per cent during the same period. On the other hand, BSE Smallcap index tumbled 1.17 per cent during the same period.

 
Markets weekly: Sensex plunges 187 points on US rate hike worries; P-note tightening

2016-05-21 financialexpress
Concerns over record losses posted by public sector banks and possibility of an interest rate hike by the US Federal Reserve as early as June impacted market sentiments this week. As a result, benchmark indices BSE Sensex and NSE Nifty shed nearly a percentage point for the week ended May 20.

 
Spicejet among 14 stocks that surged over 100% on BSE 500 in one year

2016-05-05 financialexpress
The benchmark BSE Sensex slid 8.69 per cent to 25,101.73 in the past one year till May 4 following uncertainty due to Chinese yuan devaluation and weak corporate earnings. The index was at 27,490.59 on the same day a year ago.

 
Stocks that surged over 100% in the past one year

2016-02-03 financialexpress
Out of 191 stocks, shares of Rajesh Exports surged the most — 318 per cent, followed by SpiceJet (up 291 per cent), Gayatri Projects (up 275 per cent), Kwality Ltd (up 202 per cent) and Nilkamal (up 201 per cent).

Related Articles

ACIA: Acacia Communications Analysis and Research Report

3m - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...